NCT06314295

Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods

Beijing Hospital·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Coronary Artery Disease
Study type
Observational
Sponsor & location
Primary sponsor
Beijing Hospital
Timeline & enrollment
Phase
N/A
Start date
Mar 11, 2024
End date
Apr 11, 2026
Enrollment
1500 participants
Primary outcome

Different coronary angiography results

Summary

The incidence rate and mortality of coronary artery disease are increasing year by year.
 Exploring non-invasive, accurate, and widely applicable methods to screen and diagnosis is of
 great significance. New ultrasound techniques, such as non-invasive myocardial work, have
 been proven to be superior to traditional ultrasound techniques in screening and diagnosis.
 However, diagnostic analysis based on ultrasound video images is time-consuming and
 subjective. The progress of artificial intelligence technology in fully automated
 quantitative evaluation of video images provides the possibility for computer-aided design
 screening and diagnosis. At present, the application of artificial intelligence in
 computer-aided design is a cutting-edge issue in the field of cardiovascular disease
 research. The application of artificial intelligence technology in the construction of
 computer-aided diagnostic models based on ultrasound video images is still in its early
 stages.

ICD-10 classifications
Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06314295
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06314295 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Hospital and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 1500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.